Nephrosis, Lipoid clinical trials
The registry lists 75 studies for Nephrosis, Lipoid across more than 10 countries. 32 are recruiting or about to start. 36 of them are mainly about Nephrosis, Lipoid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Nephrosis, Lipoid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Assistance Publique - Hôpitaux de Paris (10) · University of Michigan (5) · Northwell Health (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2) · Goldfinch Bio, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Mario Negri Institute for Pharmacological Research (2) · University Hospital, Limoges (2)
What is being tested here
Drugs under test in Nephrosis, Lipoid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Obinutuzumab | 2 | 0 | 2 |
| Sibeprenlimab | 1 | 0 | 1 |
| Human plasma | 1 | 0 | 1 |
| Ripertamab | 1 | 1 | 1 |
| N-acetylmannosamine | 1 | 0 | 1 |
| Frexalimab | 1 | 0 | 1 |
| Brivekimig | 1 | 0 | 1 |
| Rilzabrutinib | 1 | 0 | 1 |
| Sparsentan | 1 | 0 | 1 |
| BAT4406F | 1 | 1 | 1 |
Drug classes tested here Corticosteroids 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7
- Dec 2026A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease · Sanofi
- Jan 2027INS, B Cells and Microbiota · Nantes University Hospital
- Mar 2027Study of WAL0921 in Patients With Glomerular Kidney Diseases · Walden Biosciences
- Mar 2027A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) · Northwell Health
- Mar 2027taVNS for FRNS in Children · Northwell Health
- Mar 2027Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases · Travere Therapeutics, Inc.
- Aug 2027Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes · Assistance Publique - Hôpitaux de Paris
Who these studies take
Of the 24 Nephrosis, Lipoid studies recruiting now, 10 (42%) set no upper age limit and 9 (38%) stop at 75 or younger. 16 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 14 (58%) | 14 (58%) |
| 18 | 21 (88%) | 21 (88%) |
| 30 | 19 (79%) | 19 (79%) |
| 40 | 19 (79%) | 19 (79%) |
| 50 | 19 (79%) | 19 (79%) |
| 65 | 19 (79%) | 19 (79%) |
| 75 | 19 (79%) | 19 (79%) |
| 85 | 13 (54%) | 13 (54%) |
Across all 75 studies, recruiting or not: 40% stop at 75 or younger and 32% at 65; 56% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 75. Browse all 75 → or search them.
- NEPTUNE Match StudyRecruitingNCT04571658Not applicable1 country
- Nephrotic Syndrome Study NetworkRecruitingNCT012090002 countries
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte DiseasesRecruitingNCT06664814Phase 21 country
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingNCT06500702Phase 222 countries
- A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingNCT07861113Phase 2
- A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)RecruitingNCT07710157Phase 23 countries
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Phase 21 country
- Study of WAL0921 in Patients With Glomerular Kidney DiseasesRecruitingNCT06466135Phase 27 countries
- Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome.Not yet recruitingNCT07685093Not applicable
- Epithelial Dysmetabolism and Renal Fibrosis in ANCA VasculitisRecruitingNCT070102501 country
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingNCT05003986Phase 28 countries
- Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change DiseaseRecruitingNCT056506191 country
- A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)RecruitingNCT05583942Not applicable1 country
- taVNS for FRNS in ChildrenRecruitingNCT05588063Not applicable1 country
- SLIT ABS: Study on Patients With Autoimmune PodocytopathyRecruitingNCT07516964Not applicable5 countries
- A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisRecruitingNCT07499700Phase 2/31 country
- A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.RecruitingNCT042075802 countries
- INS, B Cells and MicrobiotaRecruitingNCT049247121 country
- Obinutuzumab in Adult Rituximab-Dependent Nephrotic SyndromeNot yet recruitingNCT07233330Phase 21 country
- Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.RecruitingNCT055055001 country
- The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)RecruitingNCT039499721 country
- Autoantibodies Against-nephrin in Idiopathic Nephrotic SyndromeRecruitingNCT063346921 country
- Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID StudyNot yet recruitingNCT07151456Phase 41 country
- Non-invasive Diagnosis of Idiopathic Nephrotic SyndromesRecruitingNCT068208661 country
- Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics StudyNot yet recruitingNCT06792448
- Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1Not yet recruitingNCT064430341 country
- Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCDNot yet recruitingNCT06405100Phase 3
- Circulating Factors in Nephrotic SyndromeNot yet recruitingNCT06315504
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- China Kidney Patient Trials NetworkRecruitingNCT050368501 country
- INSIGHT (Insight Into Nephrotic Syndrome)RecruitingNCT016052661 country
- KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisRecruitingNCT039298871 country
- Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic SyndromeActive, not recruitingNCT05914155Phase 31 country
- Immunophenotyping Profiling in Patients With Primary Nephrotic SyndromeCompletedNCT077029811 country
- Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney FailureActive, not recruitingNCT021945821 country
- REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)Active, not recruitingNCT06635720Phase 31 country
- Global Kidney Patient Trials NetworkCompletedNCT043898271 country
- UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)CompletedNCT04075656Not applicable1 country
- Active Vitamin D and Reduced Dose Prednisolone for Treatment in Minimal Change NephropathyCompletedNCT03210688Phase 41 country
- A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic SyndromeCompletedNCT01763580Phase 41 country
- Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseCompletedNCT04009668Phase 21 country
- Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)TerminatedNCT05441826Phase 21 country
- Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic SyndromeWithdrawnNCT05599815Phase 21 country
- Reduce Immunosuppression With Atmp in NS ChildrEnCompletedNCT04034316Phase 21 country
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With ProteinuriaCompletedNCT05314231Phase 11 country
- Application of Hyperspectral Imaging in the Diagnosis of Glomerular DiseasesStatus unknownNCT05797051
- Rituximab for Idiopathic Nephrotic SyndromeCompletedNCT04494438Phase 31 country
- A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseTerminatedNCT04387448Phase 21 country
- Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic SyndromeCompletedNCT04169776Not applicable1 country
- Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in ChildrenCompletedNCT02818738Phase 31 country